The double-blind, placebo-controlled trial will recruit 100 patients with COVID-19 who require oxygen but are not in the ICU. The endpoints include incidence of renal failure and incidence of respiratory failure.
TXA127 is a Mas receptor agonist and has been shown in various animal models of lung injury to reduce inflammation, stabilize endothelial and epithelial barriers and reduce fibrosis.
Constant previously announced plans for three additional Phase 2 trials at the Brigham and Women's Hospital in Boston, Massachusetts; Policlinico S. Orsola-Malpighi Hospital in Bologna, Italy; and at sites in Israel affiliated with Bar-Ilan University and Technion Israel Institute of Technology.
TXA127 is a pharmaceutical formulation of the naturally occurring human peptide angiotensin-(1–7). In addition to its specific effects in lung injury, TXA127 has shown therapeutic activity in animal models of chronic stroke, Duchenne Muscular Dystrophy, Limb–Girdle Muscular Dystrophy, Congenital Muscular Dystrophy (MDC1A), Marfan Syndrome and Epidermolysis Bullosa.
Constant Therapeutics LLC is a private biopharmaceutical company developing drugs that target the alternative renin angiotensin system, the protective arm of the renin angiotensin system.
This protective pathway involves the enzyme ACE2, its principal product, the peptide angiotensin-(1-7), and the peptide's target, the Mas receptor. Constant's lead drug candidate is TXA127.
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins